Inhibikase Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	0.26	0.12	3.1
Revenue Growth (YoY)	-	-	111.03%	-96.02%	343.92%
Gross Profit	-	-	0.26	0.12	3.1
Selling, General & Admin	23.56	11.38	6.73	6.22	6.51
Research & Development	29.79	17.21	13.62	12.04	11.36
Other Operating Expenses	1.37	-	-	-	-
Total Operating Expenses	54.72	28.59	20.35	18.25	17.87
Operating Income	-51.97	-28.59	-20.09	-18.13	-14.77
Interest Income	3.72	1.07	1.06	0.07	-0.02
Total Non-Operating Income (Expense)	3.72	1.07	1.06	0.07	-0.02
Pretax Income	-48.26	-27.52	-19.03	-18.05	-14.79
Net Income	-48.26	-27.52	-19.03	-18.05	-14.79
Net Income to Common	-48.26	-27.52	-19.03	-18.05	-14.79
Shares Outstanding (Basic)	98	24	6	4	3
Shares Outstanding (Diluted)	98	24	6	4	3
Shares Change (YoY)	314.60%	293.35%	42.74%	39.15%	121.72%
EPS (Basic)	-0.49	-1.16	-3.16	-4.28	-4.86
EPS (Diluted)	-0.49	-1.16	-3.16	-4.28	-4.86
Shares Outstanding	131.69	69.36	6.19	4.22	4.19
Free Cash Flow	-27.8	-19.15	-18.1	-17.59	-14.3
Free Cash Flow Per Share	-0.28	-0.81	-3.00	-4.17	-4.71
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-7711.98%	-14686.20%	-476.23%
Profit Margin	-	-	-7304.73%	-14625.90%	-476.88%
FCF Margin	-	-	-6947.87%	-14253.40%	-461.10%
EBITDA	-51.91	-28.56	-19.91	-18.12	-14.77
EBITDA Margin	-	-	-7643.88%	-14680.70%	-476.23%
EBIT	-51.97	-28.59	-20.09	-18.13	-14.77
EBIT Margin	-	-	-7711.98%	-14686.20%	-476.23%

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q